A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
09/2002
09/18/2002	CN1370240A Regulation system of expression using nuclear PPAR receptors
09/18/2002	CN1370238A Human poly(ADP-ribose) polymerase 2 materials and methods
09/18/2002	CN1370232A Methods for making APO-2 ligand using divalent metal ions
09/18/2002	CN1370231A CASB618 polynucleotides and polypeptides and their use
09/18/2002	CN1370201A Polymeric compsn. for solubilizing poorly water soluble drugs and process for prepn. thereof
09/18/2002	CN1370182A Compounds and methods for therapy and diagnosis of lung cancer
09/18/2002	CN1370181A Effectors of dipeptidyl peptidase IV for topical use
09/18/2002	CN1370083A Ninovasive genetic immnization, expression products therefrom, and uses thereof
09/18/2002	CN1370078A Prion protein peptides and uses thereof
09/18/2002	CN1370076A HM 1.24 antigen expression potentiators
09/18/2002	CN1370074A Method of treating malignancies and viral infections and improving immune function with dietary supplement
09/18/2002	CN1370069A Use of CGRP antagonists and CGRP release inhibitors for controlling menopausal hot flashes
09/18/2002	CN1370054A Growth promoting compsns. for mammals and method of promoting growth of mammals by using same
09/18/2002	CN1369561A Cell factor CK-HA and its variant with hematogenesis promoting and immunoregulating functions
09/18/2002	CN1369507A Process for separating megakaryocyte stimulating factor from human plasma and purifying it and its application
09/18/2002	CN1369309A Third-generation nutritive SOD capsule
09/18/2002	CN1090971C Uropoly acid-peptide compsn.
09/18/2002	CN1090970C Process for preparing uropoly acid-peptide compsn.
09/17/2002	USRE37850 Recombinant human endothelial cell growth factor
09/17/2002	US6451994 Polypeptides, polynucleotides; drug screening; diagnosing alzheimers, parkinsons, huntington*s, and creutzfelt-jacob disease; amyotrophic lateral sclerosis, cystic fibrosis
09/17/2002	US6451993 Polynucleotides encoding human excitatory amino acid transporter 4 (EAAT4)
09/17/2002	US6451983 Tumor necrosis factor antibodies
09/17/2002	US6451982 Polypeptide with amino acid sequences grafted into human heavy and light chain variable regions
09/17/2002	US6451981 Inhibitor of cellular adhesion, migration or infiltration into areas of tissue damage, injury, or transplant
09/17/2002	US6451976 Bi-or multifunctional molecules based on a dendroaspin scaffold
09/17/2002	US6451972 Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors
09/17/2002	US6451971 Polypeptide cell adhesion inhibitors; antimetastasis and anticarcinogenic agents
09/17/2002	US6451969 Polypeptide binds lectin; inhibits carbohydrate binding to selectin
09/17/2002	US6451968 Hoogsteen type base pairing in triplex motif; diagnosis; heat resistance; detection of point mutations, restriction enzyme sites, and transcription inhibition
09/17/2002	US6451853 Small molecules that elicit a polarized Th1 response and for modulation of cellular immunity
09/17/2002	US6451840 Regulation of T cell-mediated immunity by tryptophan
09/17/2002	US6451817 Alpha-substituted-1-benzyl-napthyls
09/17/2002	US6451776 Water soluble prodrugs of hindered alcohols
09/17/2002	US6451765 Methods for treating breast cancer using Mammastatin
09/17/2002	US6451764 VEGF-related protein
09/17/2002	US6451763 Retinal pigmented epithelium derived neurotrophic factor and methods of use
09/17/2002	US6451762 Protracted acting, water-soluble aggregates of derivatives of human insulin, derivatives of human insulin capable of forming such aggregates, pharmaceutical compositions containing them, and to the use of such aggregates in the
09/17/2002	US6451761 N′N′-dichlorinated omega-amino acids and uses thereof
09/17/2002	US6451760 Treatment of inflammation using a 2F1 polypeptide or an antibody thereto
09/17/2002	US6451602 Hybridizable oligonucleotides
09/17/2002	US6451579 Regulated expression of recombinant proteins using RNA viruses
09/17/2002	US6451577 Human uridine disphosphate galactose-4-epimerase
09/17/2002	US6451575 The invention is directed to the family of aggrecan degrading metallo proteases (admps) that exhibit the ability to cleave the aggrecan core protein between amino acid residues glu.sup.373 -ala.sup.374. the invention encompasses the
09/17/2002	US6451571 Isolated nucleic acid molecules encoding a herpesviridae thymidine kinase enzyme comprising one or more mutations, at least one of the mutations encoding an amino acid substitution upstream from a drh nucleoside binding site which increases a
09/17/2002	US6451562 Polypeptides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) polynucleotides
09/17/2002	US6451561 Growth hormone variants
09/17/2002	US6451557 Method for producing, in yeast, a hydroxylated triple helical protein, and yeast host cells useful in said method
09/17/2002	US6451556 EF-Tu
09/17/2002	US6451549 Encoded by a polynucleotide; use as reporter molecule
09/17/2002	US6451545 Monoclonal antibody specific to anti-human fibrin monomer, process for producing the same, hybridomas, and immunoassay method
09/17/2002	US6451541 Chaperones capable of binding to prion proteins and distinguishing the isoforms PrPc and PrPsc
09/17/2002	US6451538 Antisense modulation of CHK2 expression
09/17/2002	US6451523 Variant form of the receptor for the obese gene product. the invention relates to methods of detecting this receptor variant in cells and tissues of obese individuals.
09/17/2002	US6451349 Basification of zinc-insulin dissolved in acid; forming microparticles; administering to lungs
09/17/2002	US6451347 Complexing oxidized or deamidated human growth hormone with metal; precipitation, isolation
09/17/2002	US6451346 Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
09/17/2002	US6451341 Time release formulation of vitamins, minerals and other beneficial supplements
09/17/2002	US6451339 Drug delivery
09/17/2002	US6451326 Cosmetic compositions
09/17/2002	US6451318 Secreted proteins
09/17/2002	US6451315 Compounds and methods for the diagnosis and treatment of B. microti infection
09/17/2002	US6451313 Heterotetramer; expression vectors encoding heavy and light chains; viricides
09/17/2002	US6451312 Diagnosis, imaging; induction of endothelial cell surface antigens
09/17/2002	US6451310 Preventing t cell activation of b cells by administering antibody cabable of binding protein recognized by monoclonal antibody 5c8
09/17/2002	US6451308 Administering mutant polypeptide to treat rheumatoid arthritis and as immunomodulator
09/17/2002	US6451307 3′-exonuclease, production and use thereof
09/17/2002	US6451306 Specific protocol for use in grafting donor cells genetically modified to produce nerve growth factors into grafting sites within the cholinergic basal forebrain and is especially useful in treating neurodegenerative conditions such as
09/17/2002	US6451305 Methods for stimulating T cell responses to tumor cells expressing LFA-3 and a CD28 or CTLA4 ligand
09/17/2002	US6451303 Method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels in a human patient in need of treatment for coronary artery disease an effective amount of a recombinant fibroblast
09/17/2002	US6451286 Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
09/17/2002	US6450681 Dissolving in liquid; agitation
09/17/2002	CA2243459C Human antibodies that bind human tnf.alpha.
09/17/2002	CA2242693C Additive formulation and method of use thereof
09/17/2002	CA2213001C Isolated nucleic acid molecule encoding peptides which form complexes with mhc molecule hla-cw*1601 and uses thereof
09/17/2002	CA2204151C Cdna encoding a bmp type ii receptor
09/17/2002	CA2187908C Non-splicing variants of gp350/220
09/17/2002	CA2172989C Conotoxin peptides
09/17/2002	CA2129976C Peptidyl derivatives as inhibitors of interleukin-1.beta. converting enzyme
09/17/2002	CA2122036C Bacterial nitroreductase for the reduction of cb 1954 and analogues thereof to a cytotoxic form
09/17/2002	CA2113118C Novel growth factor-responsive progenitor cells which can be proliferated in vitro
09/17/2002	CA2111853C Substantially pure receptor like tgf-.beta.1 binding molecules and uses thereof
09/17/2002	CA2080272C Cyclic vasoactive peptides
09/17/2002	CA2072420C Storage of materials
09/17/2002	CA2067919C Heterobifunctional antibodies possessing dual catalytic and specific antigen binding properties and methods using them
09/17/2002	CA2047244C Genetically engineered immunoglobulins
09/17/2002	CA2045473C Compositions for treating ischemia-related neuronal damage
09/17/2002	CA2038667C Process for the preparation of mannosyl teicoplanin derivatives and mannosyl teicoplanin aglycone
09/16/2002	CA2376131A1 A method for the production of pharmaceutically active recombinant urokinase
09/14/2002	CA2376716A1 Use of a c1 esterase inhibitor for preventing or delaying rejection of xenotransplants in mammals
09/12/2002	WO2002071064A1 Method of examining steroid-responsiveness
09/12/2002	WO2002071062A2 Diagnosis and treatment of inflammation and hyperactive immune conditions
09/12/2002	WO2002070755A2 Fen endonucleases
09/12/2002	WO2002070715A1 Human g-type lysozyme, the encoding sequence, preparing method and the uses thereof
09/12/2002	WO2002070711A1 Vaccine
09/12/2002	WO2002070709A2 Molecules for disease detection and treatment
09/12/2002	WO2002070708A2 Glutamate receptor modulatory proteins and nucleic acids encoding them
09/12/2002	WO2002070707A2 Novel gpcr-like proteins and nucleic acids encoding same
09/12/2002	WO2002070706A2 Interleukin-8 homologous polypeptides and therapeutic uses thereof
09/12/2002	WO2002070704A2 Adipocyte complement related protein zacrp11
09/12/2002	WO2002070701A2 Novel human gnrh receptor

1 ... 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 ... 3163